Eli Lilly & Co., a world-leading and global pharmaceutical company headquartered in Indianapolis in the state of Indiana, revealed that it will pay $8 billion in cash for cancer drug specialists Loxo Oncology, marking the second-biggest pharmaceutical deal of the year so far, per The Street.
Per the same announcement, the deal will see Eli Lilly pay an amount of $235 per share of Loxo, an amount which, per the company’s closing stocks last Friday of $139.87, represents a premium of 68 percent. Both companies also stated that the deal should be closed by the time the first quarter of 2019 ends. It’s also not subject to any financing condition of any sort.
Jacob Van Naarden, Chief Operating Officer for Loxo Oncology, said, “We are excited to have reached this agreement with a team that shares our commitment to ensuring that emerging translational science reaches patients in need. We are confident that the work we have started, which includes an FDA approved drug, and a pipeline spanning from Phase 2 to discovery, will continue to thrive in Lilly’s hands.”
Good news for both companies
After news of the deal started circulating, both companies saw their shares increase, with Eli Lilly’s going up by 0.7 percent while Loxo’s surged by up to 65.9 percent. Part of this surge can also be attributed to news that the deal would take the Stamford, Connecticut-based biotech’s market value past $7.1 billion, increasing stock prices up to $232.06.
Per Eli Lilly, the transaction with Loxo Oncology will definitely impact its recently announced 2019 earnings guidance. However, the company assured that it will be updating its investors when the company publishes fourth-quarter and full-year earnings come Feb. 13.
Boosts and earnings
Thanks in part to stronger demand for new medicines and its leading drug franchise for diabetes, Eli Lilly was able to confidently boost its quarterly dividend and issued 2019 profits forecasts that can be observed as bigger than what the company previously expected.
The company expects its full-year 2019 earnings to be between $5.90 and $6.10 per share, and its next quarter dividend payout to rise by 15 percent to 64.5 cents per share. These numbers are higher than the previous one, which only goes up to $5.55 to $5.60 per share on a non-GAAP basis.
Furthermore, the company was also able to recently release Trulicity, a drug which can reduce the risk of major adverse cardiac instances in patients. With the new drug, the company was able to earn sales of $816.2 million, a number that is much stronger than what the company previously expected.
REE Reflects on ESG Recovery at its 2021 Sustainability Workshops
The Red Electrica Group is initiating a new line of action in four major critical areas. The first is the...
Nigeria Launches eNaira After One-Month Delay
CBDCs work just like the money people see in their bank accounts. The central bank will have complete control over...
DIAFASUD: An Initiative of the Burkinabe Diaspora in the US to Contribute to Africa’s Development
The Diaspora for the Sustainable Development of Africa (DIAFASUD) is the new NGO that was officially presented to the Burkinabe...
How Speculative Profit-Taking is Affecting the Prices of Vegetable Oils Futures
World vegetable oils prices were higher last week, but the markets came off the highs late in the week on...
Extremadura Subsidizes R&D&I Projects for Covid-19 Containment with €3 million
As a whole, with the resolution of the two calls that have been approved for the sanitary containment of the...
Cannabis2 weeks ago
ArgenCann Will Be Part of Expo Cannabis 2021
Crypto2 weeks ago
Filecoin Price Forecast: FIL Could Soon Increase by 18%
Featured2 weeks ago
Rice Demand Was Improved Last Week Over the Previous Week
Business2 weeks ago
Augmented Reality Investment Is Heating Up: Magic Leap, XRApplied